8-K: RxSight Q2 2025: LAL Growth Amid Revenue Dip

RxSight, Inc. reported mixed second quarter 2025 financial results, with increased Light Adjustable Lens procedure volume offset by a decline in Light Delivery Device sales, leading to a 4% revenue decrease and expanded net loss, while reaffirming full-year guidance.

Summary

• Second quarter 2025 revenue was $33.6 million, representing a 4% decrease compared to the second quarter of 2024.
• The sale of Light Adjustable Lenses (LAL/LAL+) increased by 13% to 27,380 units in Q2 2025 compared to Q2 2024.
• The sale of Light Delivery Devices (LDDs) decreased by 49% to 40 units in Q2 2025 compared to Q2 2024.
• The installed base of LDDs reached 1,084 as of June 30, 2025, a 34% increase from 810 LDDs at the end of Q2 2024.
• Gross profit for Q2 2025 was $25.2 million, or 74.9% of revenue, an increase from $24.3 million (69.5% of revenue) in Q2 2024, primarily due to a favorable shift in product mix toward LAL sales.
• Total operating expenses for Q2 2025 were $39.2 million, a 20% increase from $32.6 million in Q2 2024, reflecting investments to support LAL sales volume and advance research and development.
• Net loss for Q2 2025 was $(11.8) million, or $(0.29) per basic and diluted share, compared to a net loss of $(6.1) million, or $(0.16) per share, in Q2 2024.
• Adjusted net loss for Q2 2025 was $(3.2) million, or $(0.08) per basic and diluted share, compared to an adjusted net gain of $26,000, or $0.00 per share, in Q2 2024.
• Cash, cash equivalents, and short-term investments decreased by $1.8 million to $227.5 million as of June 30, 2025, from $229.3 million as of March 31, 2025.
• Received FDA approval to expand the Light Adjustable Lens dioptric power range to -2.0 to +3.0 diopters, along with approvals for new LDD software updates.
• Launched the RxSight Light Adjustable Lens system in South Korea during Q2 2025, with a subsequent launch in Singapore in July 2025.
• Announced a realignment of its commercial organization and launched a Customer Success Organization.
• Reaffirmed its 2025 full-year guidance: revenue of $120.0 million to $130.0 million (implied decrease of 14% to 7% compared to 2024), gross margin in the range of 72% to 74% (implied increase of 130 to 330 basis points compared to 2024), and operating expenses in the range of $145.0 million to $155.0 million (implied increase of 7% to 14% compared to 2024).

Sentiment

Score: 5

Explanation: The sentiment is neutral. While the company reported a decrease in overall revenue and an increased net loss, these were largely driven by a significant drop in Light Delivery Device (LDD) sales, which are less frequent purchases. Positively, the higher-margin Light Adjustable Lens (LAL) procedure volume increased by 13%, and gross profit margin improved. The reaffirmation of full-year guidance suggests the results are within management's expectations, but the decline in LDD sales and widening net loss present challenges that temper enthusiasm.

Positives

• Light Adjustable Lens (LAL/LAL+) procedure volume increased by 13% to 27,380 units in Q2 2025 compared to Q2 2024, indicating strong adoption of the core product.
• Gross profit margin improved significantly to 74.9% in Q2 2025 from 69.5% in Q2 2024, driven by a favorable shift in product mix towards higher-margin LAL sales.
• The installed base of Light Delivery Devices (LDDs) grew by 34% to 1,084 units as of June 30, 2025, from 810 units in Q2 2024, demonstrating continued expansion of the system's footprint.
• Received FDA approval to expand the Light Adjustable Lens dioptric power range to -2.0 to +3.0 diopters, enhancing product versatility and market applicability.
• Successfully launched the RxSight Light Adjustable Lens system in new international markets, South Korea in Q2 2025 and Singapore in July 2025, indicating progress in global expansion.
• Reaffirmed full-year 2025 guidance for revenue, gross margin, and operating expenses, providing a degree of predictability and stability to investors.
• Strategic initiatives, including the realignment of the commercial organization and the launch of a Customer Success Organization, are designed to accelerate growth and deepen customer engagement.

Negatives

• Total revenue decreased by 4% to $33.6 million in Q2 2025 compared to $34.9 million in Q2 2024.
• Light Delivery Device (LDD) sales decreased significantly by 49% in Q2 2025 compared to Q2 2024, with only 40 units sold.
• Net loss expanded to $(11.8) million, or $(0.29) per basic and diluted share, in Q2 2025, compared to a net loss of $(6.1) million, or $(0.16) per share, in Q2 2024.
• Adjusted net loss was $(3.2) million in Q2 2025, a decline from an adjusted net gain of $26,000 in Q2 2024.
• Total operating expenses increased by 20% to $39.2 million in Q2 2025, reflecting ongoing investments that contributed to the increased net loss.
• Cash, cash equivalents, and short-term investments decreased by $1.8 million from March 31, 2025, to $227.5 million as of June 30, 2025.

Risks

• Forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from those expressed or implied.
• Specific risk factors are detailed in the section entitled Part II, Item 1A (Risk Factors) in the Quarterly Report on Form 10-Q for the three months ended June 30, 2025, which is not included in this filing.

Future Outlook

The company reaffirmed its 2025 full-year guidance for revenue, gross margin, and operating expenses. Management anticipates accelerating growth by deepening engagement with existing customers and strategically expanding its installed base of Light Delivery Devices (LDDs). Newly launched initiatives, including a Customer Success Organization and realigned commercial structure, along with targeted investments in clinical affairs, marketing, and education, are expected to enhance customer support, advance post-operative vision optimization, and drive sustained growth by fully realizing the clinical value of the Light Adjustable Lens.

Management Comments

• "With nearly 1,100 LDD-enabled practices in place, we see significant opportunity to accelerate growth by deepening engagement with our existing customers while strategically expanding our installed base."
• "Our newly launched Customer Success Organization, supported by targeted investments in clinical affairs, marketing, and education, is designed to elevate onboarding, strengthen ongoing practice support and advance the mastery of post-operative vision optimization."
• "Together with our realigned commercial structure and selective investments in high-impact areas, these initiatives position us to fully realize the clinical value of the LAL and drive sustained growth."

Industry Context

RxSight operates in the ophthalmic medical device sector, specifically focusing on advanced intraocular lenses for cataract surgery. The company's Light Adjustable Lens (LAL) system offers a unique post-operative adjustability feature, differentiating it from standard IOLs. The reported increase in LAL procedure volume suggests continued adoption of this innovative technology within the cataract surgery market, despite a slowdown in new Light Delivery Device (LDD) placements. The expansion into South Korea and Singapore indicates a strategic push for international market penetration, aligning with broader trends of globalizing medical device technologies. The decline in LDD sales could reflect market saturation in certain areas or a strategic shift towards maximizing utilization of the existing installed base rather than aggressive new placements.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results for direct assessment against global benchmarks.

Stakeholder Impact

• Shareholders: Mixed results with revenue decline and increased net loss, but positive LAL growth and reaffirmed guidance. The decline in LDD sales could raise concerns about future growth drivers, but the focus on LAL utilization might reassure.
• Customers (Ophthalmic Practices): Benefit from FDA approval expanding LAL dioptric range and new LDD software updates, enhancing product utility. The new Customer Success Organization aims to improve support and onboarding.
• Employees: Realignment of the commercial organization may impact roles, but overall investments in R&D and customer support suggest continued growth focus.

Next Steps

• Host a conference call on Thursday, August 7, 2025, at 1:30 p.m. Pacific Time to discuss Q2 2025 financial results.
• Continue to deepen engagement with existing customers and strategically expand the installed base of Light Delivery Devices.
• Further develop and advance the research and development pipeline.
• Continue to implement initiatives from the realigned commercial structure and Customer Success Organization to elevate onboarding, strengthen ongoing practice support, and advance post-operative vision optimization.

Key Dates

Recommendation

The company presents a mixed financial picture for Q2 2025. While the core Light Adjustable Lens (LAL) procedure volume shows healthy 13% growth and gross margins improved significantly due to a favorable product mix, the substantial 49% decline in Light Delivery Device (LDD) sales and the widening net loss are concerning. The reaffirmation of full-year guidance suggests these results were anticipated by management, but the slowdown in LDD placements could signal a maturing of the initial market penetration phase or a shift in strategy towards maximizing existing LDD utilization. Investors should hold to observe if the new commercial organization and customer success initiatives can effectively drive LAL adoption and revenue growth from the existing LDD base, and if LDD sales stabilize or find new growth avenues. The long-term potential of the LAL technology remains, but the current quarter's performance indicates a period of transition and re-evaluation of growth drivers.

Keywords

Ophthalmic, Medical Device, Cataract Surgery, Light Adjustable Lens, LAL, LDD, Intraocular Lens, IOL, Vision Correction, Eye Care, Financial Results, SEC Filing, RXST, Nasdaq